[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100561842":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":10,"centralContacts":18,"locations":24,"responsibleParty":74,"collaborators":10,"id":77,"slug":78,"hasResults":79,"nctId":80,"briefTitle":81,"officialTitle":81,"acronym":10,"eligibilityCriteria":82,"healthyVolunteers":83,"sex":84,"minAge":85,"maxAge":10,"enrollmentInfo":86,"targetDuration":10,"studyType":89,"phases":10,"briefSummary":90,"conditions":91,"keywords":10,"overallStatus":27,"whyStopped":10,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":96,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":103,"locationsCount":104},{"fullName":5,"class":6},"University of Virginia","OTHER",[8,12,15],{"label":9,"type":10,"description":11,"interventionNames":10},"Outpatient CF Cohort",null,"Not hospitalized CF group: Diagnosis of CF, age \\>30 y, with ongoing care at one of the 3 CF Centers (Dartmouth, UAB, UVA).",{"label":13,"type":10,"description":14,"interventionNames":10},"Inpatient CF Cohort","Hospitalized CF cohort: Diagnosis of CF, age \\>7 y, being admitted for intravenous antibiotic treatment of pulmonary exacerbation.",{"label":16,"type":10,"description":17,"interventionNames":10},"Healthy Controls","Healthy Volunteers without CF",[19],{"name":20,"role":21,"phone":22,"phoneExt":10,"email":23},"Agnieszka Swiatecka-Urban, MD","CONTACT","434-924-0946","AS6XX@uvahealth.org",[25,44,62],{"facility":26,"status":27,"city":28,"state":29,"zip":30,"country":31,"countryCode":32,"cosmosGeoPoint":33,"geoPoint":38,"contacts":39},"University of Alabama at Birmingham","RECRUITING","Birmingham","Alabama","35233","United States","US",{"type":34,"coordinates":35},"Point",[36,37],-86.80249,33.52066,{"lat":37,"lon":36},[40],{"name":41,"role":21,"phone":42,"phoneExt":10,"email":43},"William T Harris, MD","205-638-9583","wtharris@uabmc.edu",{"facility":45,"status":27,"city":46,"state":47,"zip":48,"country":31,"countryCode":32,"cosmosGeoPoint":49,"geoPoint":53,"contacts":54},"Dartmouth-Hitchcock Geisel School of Medicine at Dartmouth","Lebanon","New Hampshire","03756",{"type":34,"coordinates":50},[51,52],-72.25176,43.64229,{"lat":52,"lon":51},[55,59],{"name":56,"role":21,"phone":57,"phoneExt":10,"email":58},"Sladjana Skopelja-Gardner, PhD","603-667-8259","Sladjana.Skopelja-Gardner@dartmouth.edu",{"name":60,"role":61,"phone":10,"phoneExt":10,"email":10},"Alix Ashare, MD","PRINCIPAL_INVESTIGATOR",{"facility":63,"status":27,"city":64,"state":65,"zip":66,"country":31,"countryCode":32,"cosmosGeoPoint":67,"geoPoint":71,"contacts":72},"University of Virginia Children's Hospital","Charlottesville","Virginia","22908",{"type":34,"coordinates":68},[69,70],-78.47668,38.02931,{"lat":70,"lon":69},[73],{"name":20,"role":21,"phone":22,"phoneExt":10,"email":23},{"type":61,"investigatorFullName":75,"investigatorTitle":76,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"Agnieszka Swiatecka-Urban","Professor of Pediatrics","100561842","kidney-function-in-people-with-cystic-fibrosis-in-the-era-of-hemt-100561842",false,"NCT06595420","Kidney Function in People With Cystic Fibrosis in the Era of HEMT","Inclusion Criteria:\n\n1. Outpatient CF Cohort\n\n   * Diagnoses of Cystic Fibrosis\n   * Age \\> 30 years old\n   * Able to provide informed consent\n2. Inpatient CF Cohort\n\n   * Diagnoses of Cystic Fibrosis\n   * Age \\> 7 years old\n   * Able to provide informed consent and assent (where applicable)\n   * 55 PwCF frequently hospitalized for a pulmonary exacerbation (\\>1 hospital admission in the prior 12 months)\n   * 55 PwCF sporadically hospitalized for a pulmonary exacerbation (no hospital admissions in the prior 12 months)\n   * Able to provide urine sample independently\n3. Healthy Controls\n\n   * Healthy, as per participant self-report\n   * Age between 30-50 years\n   * Able to provide informed consent\n\nExclusion Criteria:\n\n1. Outpatient CF Cohort\n\n   * History of any organ transplant\n   * History of immunodeficiency\n   * Previous or current cancer diagnoses\n   * Pregnant or breastfeeding\n   * On chronic dialysis\n   * Non-compliance (demonstrated by \\<2 visits during the 12 months before enrollment)\n2. Inpatient CF Cohort\n\n   * The initiation of intravenous antibiotic therapy after hospital admission before obtaining the first blood and urine sample\n   * History of any organ transplant\n   * History of immunodeficiency\n   * Previous or current cancer diagnoses\n   * Pregnant or breastfeeding\n   * On chronic dialysis\n3. Healthy Controls\n\n   * History or current kidney disease, organ transplantation, cancer, or any other chronic illness\n   * Current use of antibiotics\n   * Urinary symptoms or UTI (dysuria, frequency, urgency)\n   * Pregnant women\n   * Menstruating on the study visit day\n   * Blood relatives of PwCF",true,"ALL","7 Years",{"count":87,"type":88},260,"ESTIMATED","OBSERVATIONAL","The purpose of this study is to find out what causes kidney disease in people with CF. The investigators will study biomarkers in the blood and urine that can either predict who is at risk or detect kidney damage early before it becomes permanent. The study will compare these markers in people with CF over time and during the treatment of lung flare-ups. It will also compare the blood and urine samples obtained from people without CF. The comparison aims to better understand the impact of cystic fibrosis and its treatment on the kidneys, as well as to develop improved methods for preventing, diagnosing, and treating kidney issues associated with CF.",[92,93,94],"Cystic Fibrosis (CF)","Chronic Kidney Disease(CKD)","Acute Kidney Injury","2026-04-27",{"date":97,"type":98},"2026-05-04","ACTUAL",{"date":100,"type":98},"2025-01-09",{"date":102,"type":88},"2027-12",{"name":5,"class":6},3]